Suzhou Highfine Biotech Co., Ltd. (SHE:301393)
China · Delayed Price · Currency is CNY 53.59
-1.51 (-2.74%)
At close: Nov 13, 2026
Suzhou Highfine Biotech Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Nov '26 Nov 12, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Dec '21 Dec 31, 2021 |
| 5,744 | 5,422 | 4,269 | 6,481 | - | - | |
Market Cap Growth | -1.19% | 27.01% | -34.13% | - | - | - |
Enterprise Value | 4,835 | 3,941 | 2,525 | 4,742 | - | - |
Last Close Price | 55.10 | 50.34 | 39.34 | 58.68 | - | - |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Nov '26 Nov 12, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Dec '21 Dec 31, 2021 |
PE Ratio | 46.63 | 47.30 | 31.85 | 65.48 | - | - |
Forward PE | - | 33.79 | 23.69 | 34.44 | - | - |
PS Ratio | 7.80 | 9.00 | 9.45 | 16.67 | - | - |
PB Ratio | 2.41 | 2.30 | 1.88 | 2.93 | - | - |
P/TBV Ratio | 2.59 | 2.48 | 1.94 | 2.96 | - | - |
P/FCF Ratio | - | - | 229.29 | - | - | - |
P/OCF Ratio | 275.31 | 69.81 | 33.78 | 73.79 | - | - |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Nov '26 Nov 12, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 6.60 | 6.54 | 5.59 | 12.20 | - | - |
EV/EBITDA Ratio | 30.29 | 28.39 | 22.43 | 51.46 | - | - |
EV/EBIT Ratio | 43.91 | 38.36 | 26.78 | 59.86 | - | - |
EV/FCF Ratio | - | - | 135.61 | - | - | - |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Nov '26 Nov 12, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.05 | 0.02 | 0.00 | 0.00 | 0.00 | 0.01 |
Debt / EBITDA Ratio | 0.72 | 0.37 | 0.03 | 0.02 | 0.01 | 0.02 |
Debt / FCF Ratio | - | - | 0.18 | - | 0.03 | 0.10 |
Net Debt / Equity Ratio | -0.37 | -0.53 | -0.75 | -0.80 | -0.33 | -0.32 |
Net Debt / EBITDA Ratio | -5.60 | -9.07 | -15.14 | -19.19 | -1.04 | -0.90 |
Net Debt / FCF Ratio | 2.21 | 9.46 | -91.52 | 54.18 | -2.76 | -5.39 |
Asset Turnover | 0.28 | 0.24 | 0.20 | 0.27 | 0.84 | 0.94 |
Inventory Turnover | 3.01 | 2.87 | 2.35 | 2.13 | 2.65 | 3.02 |
Quick Ratio | 5.88 | 6.29 | 25.54 | 27.86 | 1.96 | 2.31 |
Current Ratio | 7.11 | 7.08 | 27.32 | 29.83 | 3.23 | 3.42 |
Return on Equity (ROE) | 4.93% | 4.79% | 5.98% | 7.35% | 30.27% | 35.18% |
Return on Assets (ROA) | 2.66% | 2.57% | 2.54% | 3.43% | 16.65% | 20.20% |
Return on Invested Capital (ROIC) | 6.91% | 10.59% | 16.23% | 18.16% | 42.78% | 53.47% |
Return on Capital Employed (ROCE) | 4.40% | 4.30% | 4.10% | 3.60% | 28.90% | 33.50% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Nov '26 Nov 12, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Dec '21 Dec 31, 2021 |
Earnings Yield | 2.14% | 2.11% | 3.14% | 1.53% | - | - |
FCF Yield | -7.02% | -2.46% | 0.44% | -0.50% | - | - |
Dividend Yield | 0.76% | 0.80% | 0.98% | 0.42% | - | - |
Payout Ratio | 34.60% | 37.89% | 29.98% | 27.28% | 15.65% | 0.01% |
Buyback Yield / Dilution | 0.55% | 0.92% | -16.97% | -14.40% | -0.16% | 0.10% |
Total Shareholder Return | 1.29% | 1.72% | -15.99% | -13.98% | -0.16% | 0.10% |